12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Olodaterol: Phase II data

Boehringer reported data from a double-blind, 4-way crossover, European Phase II trial in 47 patients with COPD showing that all doses of olodaterol met the co-primary endpoints of improving FEV1 AUC from 0-12 hours and from 12-24 hours at 3 weeks. Patients received once-daily 5 or 10 µg...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >